Active Biotech AB (SE0029278555) — research page
SE · se-cm-kg/XSTO/SE0029278555 · as of 2026-11-11
Identity and listing
The issuer is Active Biotech AB, listed on Nasdaq Stockholm under ticker SE0029278555 with ISIN SE0029278555 and LEI 549300OJ44CLMRU8YE43. Security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Active Biotech AB | source · 2026-11-11 |
| exchange | Nasdaq Stockholm | source · 2026-11-11 |
| ticker | SE0029278555 | source · 2026-11-11 |
| ISIN | SE0029278555 | source · 2026-11-11 |
| LEI | 549300OJ44CLMRU8YE43 | source · 2026-11-12 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-12 |
The disclosure read
The record holds 24 filings on 23 filing days in the window 2025-11-11 to 2026-11-11. The median gap between filing days is 12.0 days, and the latest filing is 6 days before the record date of 2026-11-11. Nasdaq Stockholm peers have a median of 30.0 filings, a median cadence gap of 9.5 days and a median latency of 7.0 days across 398 issuers. Sector peer figures are not on the record. The latest filing is dated 2026-11-05 and is of type Interim report (Q1 and Q3).
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 24 | 12 | 6 |
| exchange median: Nasdaq Stockholm (398 issuers) | 30 | 9.5 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | Interim report (Q1 and Q3) | Interim report (Q1 and Q3) | Active Biotech Interim Report Q3 2026 |
| 2026-10-13 | Investor News | Investor News | First cohort under amended protocol succesfully completes safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis |
| 2026-09-30 | Investor News | Investor News | Active Biotech Strengthens Global Patent Protection for Laquinimod with Patent Grant in Japan |
| 2026-08-20 | Half Year financial report | Half Year financial report | Active Biotech Interim Report Q2 2026 |
| 2026-08-18 | Investor News | Investor News | Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis |
window 2025-11-11 to 2026-11-11 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is not on the record, and neither is its location. Auditor changes are not on the record, as this market's register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, as this market's register has no lifecycle type map yet. The halt flag is listed, not halted.
Orderability
The orderability outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
No research houses were found on the investor-relations pages read, so the count is 0.
Open research
The record holds 3 openly published research notes, all by Redeye: 2020-12-13, 2022-04-22 and 2022-11-03.
| date | publisher | note | kind |
|---|---|---|---|
| 2022-11-03 | Redeye | Active Biotech Q3 2022: Approaching important milestones | independent |
| 2022-04-22 | Redeye | Active Biotech Q1’22: Our comments and updated valuation | independent |
| 2020-12-13 | Redeye | Derisked and Repurposed | independent |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record start is not on the record.
Sources
9 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/XSTO/SE0029278555 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://www.activebiotech.com/wp-content/uploads/Redeye-active-biotech-q3-2022-approaching-important-milestones-2_ob2rcp.pdf (open research)
- 10.7
- https://www.activebiotech.com/wp-content/uploads/Redeye_Active_Biotech_Note_Q1_2022.pdf (open research)
- 10.8
- https://www.activebiotech.com/wp-content/uploads/active-biotech-initation-201214.pdf (open research)
- 10.9
- https://mcp.se-cm-kg.ai/record/XSTO/SE0029278555 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0029278555"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:fbcb86f4167db0eb.